Cargando…

Checkpoint Inhibitors and Hepatotoxicity

Uncontrolled immune response to a pathogen or any protein can lead to tissue damage and autoimmune diseases, that represent aberrant immune responses of the individual to its own cells and/or proteins. The immune checkpoint system is the regulatory mechanism that controls immune responses. Tumor cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malnick, Stephen D. H., Abdullah, Ali, Neuman, Manuela G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909829/ https://www.ncbi.nlm.nih.gov/pubmed/33494227 http://dx.doi.org/10.3390/biomedicines9020101

Ejemplares similares

Liraglutide-Induced Hepatotoxicity
por: Maor, Yaakov, et al.
Publicado: (2021)

Treating the Metabolic Syndrome by Fecal Transplantation—Current Status
por: Malnick, Stephen D. H., et al.
Publicado: (2021)

Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different
por: Malnick, Stephen D. H., et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists’ Perspectives
por: Farshidpour, Maham, et al.
Publicado: (2022)

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
por: Xing, Hui, et al.
Publicado: (2023)

Immune checkpoint inhibitor-related hepatotoxicity: A review
por: Remash, Devika, et al.
Publicado: (2021)

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Overlapping Hepatotoxicity and Colitis Associated with Immune Checkpoint Inhibitors
por: Malik, Alexander, et al.
Publicado: (2023)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Personeni, Nicola, et al.
Publicado: (2021)

Alcoholic Liver Disease: Role of Cytokines
por: Neuman, Manuela G., et al.
Publicado: (2015)

Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach
por: Bessone, Fernando, et al.
Publicado: (2022)

Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy
por: Cunningham, Morven, et al.
Publicado: (2021)

Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
por: Xu, Ze, et al.
Publicado: (2023)

Denosumab-Induced Immune Hepatitis
por: Ostrovsky, Viviana, et al.
Publicado: (2021)

Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
por: Viganò, Mauro, et al.
Publicado: (2023)

Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury
por: Doherty, Gary Joseph, et al.
Publicado: (2017)

The Intestinal Microbiome and the Metabolic Syndrome—How Its Manipulation May Affect Metabolic-Associated Fatty Liver Disease (MAFLD)
por: Malnick, Stephen D. H., et al.
Publicado: (2023)

Molecular, Viral and Clinical Features of Alcohol- and Non-Alcohol-Induced Liver Injury
por: Neuman, Manuela G., et al.
Publicado: (2022)

Manipulation of the intestinal microbiome-a slow journey to primetime
por: Kriger-Sharabi, Ofra, et al.
Publicado: (2023)

Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: A case report
por: Eleftheriotis, Gerasimos, et al.
Publicado: (2022)

Checkpoint inhibitors in hematological malignancies
por: Ok, Chi Young, et al.
Publicado: (2017)

Checkpoint Inhibitors and the Gut
por: Tran, Tuan, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta‐Analysis
por: Fu, Jianyang, et al.
Publicado: (2021)

Isoniazid metabolism and hepatotoxicity
por: Wang, Pengcheng, et al.
Publicado: (2016)

Imidazopyranotacrines as Non-Hepatotoxic, Selective Acetylcholinesterase Inhibitors, and Antioxidant Agents for Alzheimer′s Disease Therapy
por: Boulebd, Houssem, et al.
Publicado: (2016)

Liver Injury Induced by Anticancer Chemotherapy and Radiation Therapy
por: Maor, Y., et al.
Publicado: (2013)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Structure and Optimization of Checkpoint Inhibitors
por: Picardo, Sarah L., et al.
Publicado: (2019)

Determinants of Resistance to Checkpoint Inhibitors
por: Tran, Linda, et al.
Publicado: (2020)

Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments
por: Raufi, Ali, et al.
Publicado: (2017)

International Symposium on Hepatotoxicity
por: Bloomer, Joseph R.
Publicado: (1975)

Hepatotoxicity Secondary to Chemotherapy
por: Grigorian, Alla, et al.
Publicado: (2014)

Macrophage pathology in hepatotoxicity
por: Yamate, Jyoji, et al.
Publicado: (2022)

Mechanisms of immune checkpoint inhibitor-mediated liver injury
por: Shojaie, Layla, et al.
Publicado: (2021)

Hepatotoxicity of molecular targeted therapy
por: Karczmarek-Borowska, Bożenna, et al.
Publicado: (2014)

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors
por: Rajani, Karishma R., et al.
Publicado: (2015)

Mycophenolate mofetil for immune checkpoint inhibitor‐related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review
por: Ueno, Masayuki, et al.
Publicado: (2022)

The cell cycle checkpoint inhibitors in the treatment of leukemias
por: Ghelli Luserna di Rora’, A., et al.
Publicado: (2017)

Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency
por: Maliepaard, Marc, et al.
Publicado: (2023)

The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
por: Koustas, Evangelos, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tcrmgo4vj03h86m2nfnce232em